目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 INCLUSIONS AND EXCLUSIONS
1.3.2 MARKETS COVERED
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 KEY DATA FROM SECONDARY SOURCES
2.2.1 PRIMARY RESEARCH
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.1.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.3 MARET SIZE ESTIMATION
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 MARKET SHARE ESTIMATION
2.6 ASSUMPTIONS FOR THE STUDY
2.7 RISK ASSESSMENT
2.8 IMPACT OF ECONOMIC RECESSION

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TECHNOLOGY ANALYSIS
5.4 INDUSTRY TRENDS
5.5 SUPPLY CHAIN ANALYSIS
5.6 TRADE ANALYSIS
5.7 PORTER'S FIVE FORCE ANALYSIS
5.8 TARIFF AND REGULATORY LANDSCAPE
5.8.1 REGULATORY ANALYSIS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATION
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR TRANSDERMAL PATCH MARKET
5.9.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN TRANSDERMAL PATCH MARKET
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT TYPE
5.10.2 AVERAGE SELLING PRICE TRENDS, BY REGION
5.11 KEY CONFERENCES & EVENTS DURING 2023-2024
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS & BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 ECOSYSTEM/MARKET MAP
5.14 ADJACENT MARKET ANALYSIS
5.15 CASE STUDY ANALYSIS
5.16 REIMBUSREMENT SCENARIO
5.17 VALUE CHAIN ANALYSIS
5.18 YC-YCC TRENDS/DISRUPTION IMPACTING CUSTOMER BUSINESS

6 TRANSDERMAL PATCH MARKET, BY PATCH TYPE, 2021-2029 (USD MILLION)
6.1 INTRODUCTION
6.2 DRUG-IN-ADHESIVE
6.2.1 SINGLE LAYER DRUG IN ADHESIVE PATCH
6.2.2 MULTI LAYER DRUG IN ADHESIVE PATCH
6.3 MATRIX PATCHES
6.4 RESERVOIR MEMBRANE PATCHES
6.5 MICRONEEDLE PATCHES
6.7 VAPOUR PATCHES

7 TRANSDERMAL PATCH MARKET, BY ADHESIVE TYPE, 2021-2029 (USD MILLION)
7.1 INTRODUCTION
7.2 ACRYLIC ADHESIVES
7.3 SILICONE ADHESIVES
7.4 HYDROGEL ADHESIVES
7.5 OTHER ADHESIVES

8 TRANSDERMAL PATCH MARKET, BY APPLICATION, 2021-2029 (USD MILLION)
8.1 INTRODUCTION
8.2 PAIN MANAGEMENT
8.3 HORMONAL APPLICATION
8.3.1 TRANSDERMAL TESTOSTERONE THERAPY
8.3.2 TRANSDERMAL ESTROGEN THERAPY
8.4 CENTRAL NERVOUS SYSTEM DISORDERS
8.5 CARDIOVASCULAR DISEASES
8.6 SMOKING CESSATION
8.7 OTHER APPLICATION

9 TRANSDERMAL PATCH MARKET, BY DISTRIBUTION CHANNEL, 2021-2029 (USD MILLION)
9.1 INTRODUCTION
9.2 HOSPITAL PHARMACIES
9.3 RETAIL PHARMACIES
9.4 ONLINE PHARMACIES

10 TRANSDERMAL PATCH MARKET, BY END-USER, 2021-2029 (USD MILLION)
10.1 INTRODUCTION
10.2 HOMECARE SETTINGS
10.3 HOSPITALS AND CLINICS

11 TRANSDERMAL PATCH MARKET, BY REGION, 2021-2029 (USD MILLION)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 IMPACT OF ECONOMIC RECESSION
11.2.2 US
11.2.3 CANADA
11.3 EUROPE
11.3.1 IMPACT OF ECONOMIC RECESSION
11.3.2 GERMANY
11.3.3 FRANCE
11.3.4 UK
11.3.5 ITALY
11.3.6 SPAIN
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 IMPACT OF ECONOMIC RECESSION
11.4.2 JAPAN
11.4.3 CHINA
11.4.4 AUSTRALIA
11.4.5 INDIA
11.4.6 SOUTH KOREA
11.4.7 ROAPAC
11.5 LATIN AMERICA
11.5.1 IMPACT OF ECONOMIC RECESSION
11.5.2 BRAZIL
11.5.3 MEXICO
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 IMPACT OF ECONOMIC RECESSION

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
12.4 COMPANY EVALUATION MATRIX
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
12.4.5 COMPANY FOOTPRINT
12.5 START-UPS/SME EVALUATION MATRIX
12.5.1 PROGRESSIVE COMPANIES
12.5.2 RESPONSIVE COMPANIES
12.5.3 DYNAMIC COMPANIES
12.5.4 STARTING BLOCKS
12.5.5 COMPETITIVE BENCHMARKING
12.6 MAKET SHARE ANALYSIS
12.7 COMPETITIVE SITUATION AND TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
12.7.2 DEALS
12.7.3 OTHER DEVELOPMENTS
12.8 R&D ASSESMENT OF KEY PLAYERS

13 COMPANY PROFILE
13.1 KEY PLAYERS
13.1.1 HIMAMATSU PHARMACEUTICALS CO. LTD.
13.1.2 VIATRIS
131.3 UCB S.A.
13.1.4 NOVARTIS AG
13.1.5 GLAXOSMITHKLEIN PLC
13.1.6 NITTO DENKO
13.1.7 BOOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.8 JOHNSON & JOHNSON
13.1.9 ENDO PHARMACEUTICALS INC.
13.1.10 PURDUE PHARMA L.P.
13.1.11 LAVIPHARM
13.1.12 LEAD CHEMICALS CO. LTD.
13.1.13 LUYE PHARMA GROUP
13.1.14 CIPLA
13.1.15 CLIMARA PRO
13.1.16 TEVA PHARMACEUTICALS
13.2 OTHER PLAYERS
13.2.1 AGILE THERAPEUTICS
13.2.2 ABBVIE
13.2.3 ARX LLC
13.2.4 ADHEXPHARMA
13.2.5 PROSOLUS INC.
13.2.6 IONOTOPATCH
13.2.7 LTS LOHMANN THERAPIES SYSTEM AG
13.2.8 CORIUM, INC.
13.2.9 OPTUM RX

14 APPENDIX
14.1 INSIGHTS OF INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS